Bacteria in cancer therapy: Renaissance of an old concept

International Journal of Microbiology

Volumn 2016, Issue , 2016, Pages

  Felgner, Sebastian ^a   Kocijancic, Dino ^a   Frahm, Michael ^a   Weiss, Siegfried ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84962003985     PISSN: 1687918X     EISSN: 16879198     Source Type: Journal    
DOI: 10.1155/2016/8451728     Document Type: Review

References (136)

1. N. Howlader, A. Noone, M. Krapcho, et al., SEER Cancer Statistics Review, 1975-2012, National Cancer Institute, Bethesda, Md, USA, 2014.
2. S. Crawford, "Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy, " Frontiers in Pharmacology, vol. 4, article 68, 2013.
3. U. Ringborg and A. Platz, "Chemotherapy resistance mechanisms, " Acta Oncologica, vol. 35, supplement 5, pp. 76-80, 1996.
4. D. Hanahan and R. A. Weinberg, "The hallmarks of cancer, " Cell, vol. 100, no. 1, pp. 57-70, 2000.
5. K. R. Loeb and L. A. Loeb, "Significance of multiple mutations in cancer, " Carcinogenesis, vol. 21, no. 3, pp. 379-385, 2000.
6. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
7. F. Cavallo, C. De Giovanni, P. Nanni, G. Forni, and P.-L. Lollini, "2011: The immune hallmarks of cancer, " Cancer Immunology, Immunotherapy, vol. 60, no. 3, pp. 319-326, 2011.
8. G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, "Cancer immunoediting: from immunosurveillance to tumor escape, " Nature Immunology, vol. 3, no. 11, pp. 991-998, 2002.
9. R. D. Schreiber, L. J. Old, and M. J. Smyth, "Cancer immunoediting: Integrating immunitys roles in cancer suppression and promotion, " Science, vol. 331, no. 6024, pp. 1565-1570, 2011.
10. C. G. Willett, D. G. Duda, E. dI Tomaso, et al., "Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer, " Nature Clinical Practice Oncology, vol. 4, no. 5, pp. 316-321, 2007.
11. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, "Adoptive cell transfer: a clinical path to effective cancer immunotherapy, " Nature Reviews Cancer, vol. 8, no. 4, pp. 299-308, 2008.
12. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy, " Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
13. L. M. Weiner, R. Surana, and S. Wang, "Monoclonal antibodies: versatile platforms for cancer immunotherapy, " Nature Reviews Immunology, vol. 10, no. 5, pp. 317-327, 2010.
14. B. Ebbell, The Papyrus Ebers: The Greatest Egyptian Medical Document, Levin &Munksgaard, Copenhagen, Denmark, 1937.
15. N. P. Minton, J. M. Brown, P. Lambin, and J. Anne, "Clostridia in cancer therapy, " in Clostridia, pp. 251-270, Wiley-VCHVerlag GmbH, NewYork, NY, USA, 2005.
16. W. W. Cheyne, Recent Essays by Various Authors on Bacteria in Relation to Disease, The New Sydenham Society, London, UK, 1886.
17. S. A. Hoption Cann, J. P. van Netten, and C. van Netten, "Dr William Coley and tumour regression: a place in history or in the future, " Postgraduate Medical Journal, vol. 79, no. 938, pp. 672-680, 2003.
18. W. B. Coley, "The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus, " Proceedings of the Royal Society of Medicine, vol. 3, pp. 1-48, 1910.
19. W. B. Coley, "The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and Bacillus prodigiosus. Immediate and final results in one hundred and forty cases, " Journal of the American Medical Association, vol. 16, no. 9, pp. 456-465, 1898.
20. E. F. McCarthy, "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, " The Iowa Orthopaedic Journal, vol. 26, pp. 154-158, 2006.
21. H. C. Nauts and W. E. Swift, "Thetreatment ofmalignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light ofmodern research, " Cancer Research, vol. 6, pp. 205-216, 1946.
22. H. C. Nauts, G. A. Fowler, and F. H. Bogatko, "A review of the influence of bacterial infection and of bacterial products (Coleys toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coleys mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study, " Acta Medica Scandinavica, Supplementum, vol. 276, pp. 1-103, 1953.
23. B. J. Johnston and E. T. Novales, "Clinical effect of Coleys toxin. A seven-year study, " Cancer Chemotherapy Reports, vol. 21, pp. 43-68, 1962.
24. C. Maletzki, U. Klier, W. Obst, B. Kreikemeyer, and M. Linnebacher, "Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: coleys toxin, " Clinical & Developmental Immunology, vol. 2012, Article ID 230625, 16 pages, 2012.
25. A. Morales, D. Eidinger, and A. W. Bruce, "Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors, " The Journal of Urology, vol. 116, no. 2, pp. 180-183, 1976.
26. G. Redelman-Sidi, G. Iyer, D. B. Solit, and M. S. Glickman, "Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells, " Cancer Research, vol. 73, no. 3, pp. 1156-1167, 2013.
27. G. Redelman-Sidi, M. S. Glickman, and B. H. Bochner, "The mechanism of action of BCG therapy for bladder cancer-a current perspective, " Nature Reviews Urology, vol. 11, no. 3, pp. 153-162, 2014.
28. M. R. Saban, M. A. O'Donnell, R. E. Hurst, et al., "Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α, " BMC Immunology, vol. 9, article 4, 2008.
29. H. W. Sinn, B. D. Elzey, R. J. Jensen, X. Zhao, W. Zhao, and T. L. Ratliff, "The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity, " Cancer Immunology, Immunotherapy, vol. 57, no. 4, pp. 573-579, 2008.
30. D. Morrissey, G. C. O'Sullivan, and M. Tangney, "Tumour targeting with systemically administered bacteria, " Current GeneTherapy, vol. 10, no. 1, pp. 3-14, 2010.
31. R. K. Jain and N. S. Forbes, "Can engineered bacteria help control cancer?" Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 98, no. 26, pp. 14748-14750, 2001.
32. Z.-Q. Hu and W.-H. Zhao, "Type 1 interferon-associated necroptosis: a novel mechanism for Salmonella enterica Typhimurium to induce macrophage death, " Cellular & Molecular Immunology, vol. 10, no. 1, pp. 10-12, 2013.
33. K. Westphal, S. Leschner, J. Jablonska, H. Loessner, and S. Weiss, "Containment of tumor-colonizing bacteria by host neutrophils, " Cancer Research, vol. 68, no. 8, pp. 2952-2960, 2008.
34. N. J. Roberts, L. Zhang, F. Janku, et al., "Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses, " Science TranslationalMedicine, vol. 6, no. 249, p. 249ra111, 2014.
35. V. Staedtke, R. Bai, W. Sun, et al., "Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats, " Oncotarget, vol. 6, no. 8, pp. 5536-5546, 2015.
36. T. Ruby, L. McLaughlin, S. Gopinath, and D. Monack, "Salmonellas long-termrelationshipwith its host, " FEMSMicrobiology Reviews, vol. 36, no. 3, pp. 600-615, 2012.
37. E. Choe and R. A. Kazmierczak, "Phenotypic evolution of therapeutic Salmonella enterica serovar Typhimurium after invasion of TRAMP mouse prostate tumor, " mBio: Journal Impact Factor & Description, vol. 5, no. 4, pp. 1-8, 2014.
38. S. Wang, Q. Kong, and R. Curtiss, "New technologies in developing recombinant attenuated Salmonella vaccine vectors, " Microbial Pathogenesis, vol. 58, pp. 17-28, 2013.
39. P. Chorobik, D. Czaplicki, K. Ossysek, and J. Bereta, "Salmonella and cancer: from pathogens to therapeutics, " Acta Biochimica Polonica, vol. 60, no. 3, pp. 285-297, 2013.
40. R. M. Hoffman and M. Zhao, "Methods for the development of tumor-targeting bacteria, " Expert Opinion on Drug Discovery, vol. 9, no. 7, pp. 741-750, 2014.
41. K. B. Low, M. Ittensohn, X. Luo, et al., "Construction of VNP20009, " in Suicide Gene Therapy, vol. 90 of Methods in Molecular Medicine, pp. 47-59, Humana Press, New York, NY, USA, 2004.
42. R. M. Hoffman, "Tumor-seeking Salmonella amino acid auxotrophs, " Current Opinion in Biotechnology, vol. 22, no. 6, pp. 917-923, 2011.
43. M. Zhao, M. Yang, X.-M. Li, et al., "Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella Typhimurium, " Proceedings of theNational Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 755-760, 2005.
44. Y. Zhang, N. Zhang, S. Su, R. M. Hoffman, and M. Zhao, "Salmonella Typhimurium A1-R tumor targeting in immunocompetent mice is enhanced by a traditional Chinese medicine herbal mixture, " Anticancer Research, vol. 33, no. 5, pp. 1837-1844, 2013.
45. M. Zhao, J. Geller, H. Ma, M. Yang, S. Penman, and R. M. Hoffman, "Monotherapy with a tumor-targeting mutant of Salmonella Typhimurium cures orthotopic metastatic mouse models of human prostate cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10170-10174, 2007.
46. M. Zhao, A. Suetsugu, H. Ma, et al., "Efficacy against lung metastasis with a tumor-targeting mutant of Salmonella Typhimurium in immunocompetent mice, " Cell Cycle, vol. 11, no. 1, pp. 187-193, 2012.
47. S. Miwa, S. Yano, Y. Zhang, et al., "Tumor-targeting Salmonella Typhimurium A1-R prevents experimental human breast cancer bone metastasis in nude mice, " Oncotarget, 2014.
48. Y. Hiroshima, Y. Zhang, M. Zhao, et al., "Tumor-targeting Salmonella Typhimurium A1-R in combination with Trastuzumab eradicates HER-2-positive cervical cancer cells in patientderived mouse models, " PLOS ONE, vol. 10, no. 6, Article ID e0120358, 2015.
49. A. Uchugonova, M. Zhao, Y. Zhang, M. Weinigel, K. Konig, and R. M. Hoffman, "Cancer-cell killing by engineered Salmonella imaged by multiphoton tomography in live mice, " Anticancer Research, vol. 32, no. 10, pp. 4331-4337, 2012.
50. Y. Hiroshima, M. Zhao, Y. Zhang, et al., "Tumor-targeting Salmonella Typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice, " PLOS ONE, vol. 10, no. 8, Article ID e0134324, 2015.
51. Y. Matsumoto, S. Miwa, Y. Zhang, et al., "Intraperitoneal administration of tumor-targeting Salmonella Typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice, "Oncotarget, vol. 6, no. 13, pp. 11369-11377, 2015.
52. K. M. Broadway, E. A. P. Denson, R. V. Jensen, and B. E. Scharf, "Rescuing chemotaxis of the anticancer agent Salmonella enterica serovar TyphimuriumVNP20009, " Journal of Biotechnology, vol. 211, pp. 117-120, 2015.
53. J. F. Toso, V. J. Gill, P. Hwu, et al., "Phase I study of the intravenous administration of attenuated Salmonella Typhimurium to patients with metastatic melanoma, " Journal of Clinical Oncology, vol. 20, no. 1, pp. 142-152, 2002.
54. M. Frahm, S. Felgner, D. Kocijancic, et al., "Efficiency of conditionally attenuated Salmonella enterica serovar Typhimuriumin bacterium-mediated tumor therapy, " mBio, vol. 6, no. 2, 2015.
55. J. S. Eom, J. Seok Kim, J. Im Jang, et al., "Enhancement of host immune responses by oral vaccination to Salmonella enterica serovar Typhimurium harboring both FliC and FljB Flagella, " PLoS ONE, vol. 8, no. 9, Article ID e74850, 2013.
56. S. M. Mangsbo, C. Ninalga, M. Essand, A. Loskog, and T. H. Totterman, "CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity, " Journal of Immunotherapy, vol. 31, no. 1, pp. 34-42, 2008.
57. C. T. Nguyen, S. H. Hong, J.-I. Sin, et al., "Flagellin enhances tumor-specific CD8+ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model, " Vaccine, vol. 31, no. 37, pp. 3879-3887, 2013.
58. S. Leschner and S. Weiss, "Salmonella-allies in the fight against cancer, " Journal of Molecular Medicine, vol. 88, no. 8, pp. 763-773, 2010.
59. S. Leschner, K. Westphal, N. Dietrich, et al., "Tumor invasion of Salmonella enterica serovar Typhimuriumis accompanied by strong hemorrhage promoted by TNF-α, " PLoS ONE, vol. 4, no. 8, Article ID e6692, 2009.
60. K. Crull, D. Bumann, and S. Weiss, "Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium, " FEMS Immunology and Medical Microbiology, vol. 62, no. 1, pp. 75-83, 2011.
61. C. Stern, N. Kasnitz, D. Kocijancic, et al., "Induction of CD4+ and CD8+ anti-tumor effector T cell responses by bacteria mediated tumor therapy, " International Journal of Cancer, vol. 137, no. 8, pp. 2019-2028, 2015.
62. P. C. Maciag, S. Radulovic, and J. Rothman, "The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix, " Vaccine, vol. 27, no. 30, pp. 3975-3983, 2009.
63. V. Shahabi, P. C. Maciag, S. Rivera, and A. Wallecha, "Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment, " Bioengineered Bugs, vol. 1, no. 4, pp. 237-245, 2010.
64. D. T. Le, D. G. Brockstedt, R. Nir-Paz, et al., "A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction, " Clinical Cancer Research, vol. 18, no. 3, pp. 858-868, 2012.
65. S. Barbe, L. Van Mellaert, and J. Anne, "The use of clostridial spores for cancer treatment, " Journal of Applied Microbiology, vol. 101, no. 3, pp. 571-578, 2006.
66. L. Van Mellaert, S. Barbe, and J. Anne, "Clostridium spores as anti-tumour agents, " Trends in Microbiology, vol. 14, no. 4, pp. 190-196, 2006.
67. E. L. Krick, K. U. Sorenmo, S. C. Rankin, et al., "Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors, " American Journal of Veterinary Research, vol. 73, no. 1, pp. 112-118, 2012.
68. C. Stern, The Essential Effector Role of T Cellsin Bacteria-Mediated TumorTherapy, HZI, 2012.
69. D. H. Thamm, I. D. Kurzman, I. King, et al., "Systemic administration of an attenuated, tumor-targeting Salmonella Typhimurium to dogs with spontaneous neoplasia: phase I evaluation, " Clinical Cancer Research, vol. 11, no. 13, pp. 4827-4834, 2005.
70. J. M. Pawelek, K. B. Low, and D. Bermudes, "Tumor-targeted Salmonella as a novel anticancer vector, " Cancer Research, vol. 57, no. 20, pp. 4537-4544, 1997.
71. K. B. Low, M. Ittensohn, T. Le, et al., "Lipid a mutant Salmonella with suppressed virulence and TNFα induction retain tumortargeting in vivo, " Nature Biotechnology, vol. 17, no. 1, pp. 37-41, 1999.
72. B. D. Needham, S. M. Carroll, D. K. Giles, G. Georgiou, M. Whiteley, and M. S. Trent, "Modulating the innate immune response by combinatorial engineering of endotoxin, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 4, pp. 1464-1469, 2013.
73. D. Mandell and J. E. Bennett, Principles and Practice of Infectious Diseases, Elsevier, Philadelphia, Pa, USA, 7th edition, 2010.
74. L. R. Zacharski and V. P. Sukhatme, "Coleys toxin revisited: immunotherapy or plasminogen activator therapy of cancer?" Journal of Thrombosis and Haemostasis, vol. 3, no. 3, pp. 424-427, 2005.
75. C.-H. Lee, C.-L. Wu, and A.-L. Shiau, "Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis, " Clinical Cancer Research, vol. 14, no. 6, pp. 1905-1912, 2008.
76. S. Kaimala, Y. A. Mohamed, N. Nader, et al., "Salmonellamediated tumor regression involves targeting of tumormyeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity, " Cancer Immunology, Immunotherapy, vol. 63, no. 6, pp. 587-599, 2014.
77. N. Goutagny, Y. Estornes, U. Hasan, S. Lebecque, and C. Caux, "Targeting pattern recognition receptors in cancer immunotherapy, " Targeted Oncology, vol. 7, no. 1, pp. 29-54, 2012.
78. F. Hayashi, K. D. Smith, A. Ozinsky, et al., "The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5, " Nature, vol. 410, no. 6832, pp. 1099-1103, 2001.
79. Q. Kong, J. Yang, Q. Liu, P. Alamuri, K. L. Roland, and R. Curtiss III, "Effect of deletion of genes involved in lipopolysaccharide core andO-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar Typhimurium, " Infection and Immunity, vol. 79, no. 10, pp. 4227-4239, 2011.
80. G. Nagy, V. Danino, U. Dobrindt, et al., "Down-regulation of key virulence factors makes the Salmonella enterica serovar TyphimuriumrfaH mutant a promising live-attenuated vaccine candidate, " Infection and Immunity, vol. 74, no. 10, pp. 5914-5925, 2006.
81. C. K. Schmitt, S. C. Darnell, V. L. Tesh, B. A. D. Stocker, and A. D. O'Brien, "Mutation of flgM attenuates virulence of Salmonella Typhimurium, and mutation of fliA represses the attenuated phenotype, " Journal of Bacteriology, vol. 176, no. 2, pp. 368-377, 1994.
82. S. K. Hoiseth and B. A. D. Stocker, "Aromatic-dependent Salmonella Typhimurium are non-virulent and effective as live vaccines, " Nature, vol. 291, no. 5812, pp. 238-239, 1981.
83. N. Arrach, P. Cheng, M. Zhao, C. A. Santiviago, R. M. Hoffman, and M. McClelland, "High-throughput screening for Salmonella avirulent mutants that retain targeting of solid tumors, " Cancer Research, vol. 70, no. 6, pp. 2165-2170, 2010.
84. M. K. Stewart, L. A. Cummings, M. L. Johnson, A. B. Berezow, and B. T. Cookson, "Regulation of phenotypic heterogeneity permits Salmonella evasion of the host caspase-1 inflammatory response, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20742-20747, 2011.
85. E. A. Miao and J. V. Rajan, "Salmonella and caspase-1: a complex interplay of detection and evasion, " Frontiers in Microbiology, vol. 2, article 85, 2011.
86. J. A. Hagar, D. A. Powell, Y. Aachoui, R. K. Ernst, and E. A. Miao, "Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock, " Science, vol. 341, no. 6151, pp. 1250-1253, 2013.
87. S.-I. Saitoh, S. Akashi, T. Yamada, et al., "Lipid Aantagonist, lipid IVa, is distinct fromlipidAin interactionwith Toll-like receptor (TLR4)-MD-2 and ligand-induced TLR4 oligomerization, " International Immunology, vol. 16, no. 7, pp. 961-969, 2004.
88. Q. Kong, D. A. Six, Q. Liu, et al., "Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar Typhimurium msbB mutant, " Infection and Immunity, vol. 79, no. 12, pp. 5027-5038, 2011.
89. J. S. Eom, J. Seok Kim, J. Im Jang, et al., "Enhancement of host immune responses by oral vaccination to Salmonella enterica serovar Typhimurium harboring both FliC and FljB flagella, " PLoS ONE, vol. 8, no. 9, Article ID e74850, 2013.
90. J. E. Olsen, K. H. Hoegh-Andersen, J. Casadesus, J. Rosenkranzt, M. S. Chadfield, and L. E. Thomsen, "The role of flagella and chemotaxis genes in host pathogen interaction of the host adapted Salmonella enterica serovar Dublin compared to the broad host range serovar S. Typhimurium, " BMC Microbiology, vol. 13, article 67, 2013.
91. M. D. Juarez-Rodriguez, J. Yang, R. Kader, P. Alamuri, R. Curtiss III, and J. E. Clark-Curtiss, "Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection againstMycobacterium tuberculosis, " Infection and Immunity, vol. 80, no. 2, pp. 815-831, 2012.
92. Q. Kong, Q. Liu, A. M. Jansen, and R. Curtiss, "Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines, " Vaccine, vol. 28, no. 37, pp. 6094-6103, 2010.
93. Q. Kong, Q. Liu, K. L. Roland, and R. Curtiss III, "Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar Typhimurium vaccine enhances immunogenicity of outermembrane proteins and a heterologous antigen, " Infection and Immunity, vol. 77, no. 12, pp. 5572-5582, 2009.
94. W. Kong, M. Brovold, B. A. Koeneman, J. Clark-Curtiss, and R. Curtiss III, "Turning self-destructing Salmonella into a universal DNA vaccine delivery platform, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 47, pp. 19414-19419, 2012.
95. P. Laniewski, M. Kuczkowski, K. Chrzastek, et al., "Evaluation of the immunogenicity of Campylobacter jejuni CjaA protein delivered by Salmonella enterica sv. Typhimurium strain with regulated delayed attenuation in chickens, " World Journal of Microbiology & Biotechnology, vol. 30, no. 1, pp. 281-292, 2014.
96. R. Curtiss III, S.-Y. Wanda, B. M. Gunn, et al., "Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo, " Infection and Immunity, vol. 77, no. 3, pp. 1071-1082, 2009.
97. W. Kong, S.-Y. Wanda, X. Zhang, et al., "Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 27, pp. 9361-9366, 2008.
98. S. Ashraf, W. Kong, S. Wang, J. Yang, and R. Curtiss, "Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine, " Vaccine, vol. 29, no. 23, pp. 3990-4002, 2011.
99. Y. Hiroshima, M. Zhao, Y. Zhang, et al., "Comparison of efficacy of Salmonella Typhimurium A1-R and chemotherapy on stemlike and non-stem human pancreatic cancer cells, " Cell Cycle, vol. 12, no. 17, pp. 2774-2780, 2013.
100. L.-J. Jia, H.-M. Xu, D.-Y. Ma, et al., "Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model, " Cancer Biology &Therapy, vol. 4, no. 8, pp. 840-845, 2005.
101. S. Topalian, C. Drake, and D. Pardoll, "Immune checkpoint blockade: a common denominator approach to cancer therapy, " Cancer Cell, vol. 27, no. 4, pp. 450-461, 2015.
102. D. C. Binder, B. Engels, A. Arina, et al., "Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer, " Cancer Immunology Research, vol. 1, no. 2, pp. 123-133, 2013.
103. S. S. Kwek, E. Cha, and L. Fong, "Unmasking the immune recognition of prostate cancer with CTLA4 blockade, " Nature Reviews Cancer, vol. 12, no. 4, pp. 289-297, 2012.
104. N. S. Forbes, "Engineering the perfect (bacterial) cancer therapy, " Nature Reviews Cancer, vol. 10, no. 11, pp. 785-794, 2010.
105. L. K. Green, M. A. Storey, E. M. Williams, et al., "The flavin reductase MsuE is a novel nitroreductase that can efficiently activate two promising next-generation prodrugs for genedirected enzyme prodrug therapy, " Cancers, vol. 5, no. 3, pp. 985-997, 2013.
106. J. Theys, W. Landuyt, S. Nuyts, et al., "Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum, " Cancer GeneTherapy, vol. 8, no. 4, pp. 294-297, 2001.
107. J. Nemunaitis, C. Cunningham, N. Senzer, et al., "Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients, " Cancer Gene Therapy, vol. 10, no. 10, pp. 737-744, 2003.
108. A. M. Kubiak and N. P. Minton, "The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy, " Research in Microbiology, vol. 166, no. 4, pp. 244-254, 2015.
109. J. Stritzker, S. Pilgrim, A. A. Szalay, and W. Goebel, "Prodrug converting enzyme gene delivery by L. monocytogenes, " BMC Cancer, vol. 8, article 94, 2008.
110. S.-C. Liu, G.-O. Ahn, M. Kioi, M.-J. Dorie, A. V. Patterson, and J. M. Brown, "Optimized Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104, " Cancer Research, vol. 68, no. 19, pp. 7995-8003, 2008.
111. F. Friedlos, P. Lehouritis, L. Ogilvie, et al., "Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy, " Clinical Cancer Research, vol. 14, no. 13, pp. 4259-4266, 2008.
112. C. A. Swofford, A. T. St Jean, J. T. Panteli, Z. J. Brentzel, and N. S. Forbes, "Identification of Staphylococcus aureus α-hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells, " Biotechnology and Bioengineering, vol. 111, no. 6, pp. 1233-1245, 2014.
113. A. T. St Jean, C. A. Swofford, J. T. Panteli, Z. J. Brentzel, and N. S. Forbes, "Bacterial delivery of Staphylococcus aureus α-Hemolysin causes regression and necrosis in murine tumors, " MolecularTherapy, vol. 22, no. 7, pp. 1266-1274, 2014.
114. S. Barbe, L. Van Mellaert, J. Theys, et al., "Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment, " FEMS Microbiology Letters, vol. 246, no. 1, pp. 67-73, 2005.
115. N. Yang, X. Zhu, L. Chen, S. Li, and D. Ren, "Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic, " Cancer Biology &Therapy, vol. 7, no. 1, pp. 145-151, 2008.
116. Y. Tian, B. Guo, H. Jia, et al., "Targeted therapy via oral administration of attenuated Salmonella expression plasmidvectored Stat3-shRNA cures orthotopically transplanted mouse HCC, " Cancer GeneTherapy, vol. 19, no. 6, pp. 393-401, 2012.
117. C. A. Blache, E. R. Manuel, T. I. Kaltcheva, et al., "Systemic delivery of Salmonella Typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth, " Cancer Research, vol. 72, no. 24, pp. 6447-6456, 2012.
118. R. Fronzes, P. J. Christie, and G. Waksman, "The structural biology of type IV secretion systems, " Nature ReviewsMicrobiology, vol. 7, no. 10, pp. 703-714, 2009.
119. C. Stathopoulos, D. R. Hendrixson, D. G. Thanassi, S. J. Hultgren, J. W. St Geme III, and R. Curtiss III, "Secretion of virulence determinants by the general secretory pathway in Gram-negative pathogens: an evolving story, " Microbes and Infection, vol. 2, no. 9, pp. 1061-1072, 2000.
120. C. A. Swofford, N. Van Dessel, and N. S. Forbes, "Quorumsensing Salmonella selectively trigger protein expression within tumors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 11, pp. 3457-3462, 2015.
121. J. Hardcastle, K. Kurozumi, E. A. Chiocca, and B. Kaur, "Oncolytic viruses driven by tumor-specific promoters, " Current Cancer Drug Targets, vol. 7, no. 2, pp. 181-189, 2007.
122. S. Leschner, I. V. Deyneko, S. Lienenklaus, et al., "Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logic, " Nucleic Acids Research, vol. 40, no. 7, pp. 2984-2994, 2012.
123. H. Loessner, S. Leschner, A. Endmann, et al., "Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice, " Microbes and Infection, vol. 11, no. 14-15, pp. 1097-1105, 2009.
124. H. Loessner, A. Endmann, S. Leschner, et al., "Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of l-arabinose as inducer of bacterial gene expression in vivo, " Cellular Microbiology, vol. 9, no. 6, pp. 1529-1537, 2007.
125. N. Arrach, M. Zhao, S. Porwollik, R. M. Hoffman, and M. McClelland, "Salmonella promoters preferentially activated inside tumors, " Cancer Research, vol. 68, no. 12, pp. 4827-4832, 2008.
126. H. M. Singer, M. Erhardt, A. M. Steiner, et al., "Selective purification of recombinant neuroactive peptides using the flagellar type III secretion system, " mBio, vol. 3, no. 3, 2012.
127. X. Xu, W. A. H. Hegazy, L. Guo, et al., "Effective cancer vaccine platformbased on attenuated Salmonella and a type III secretion system, " Cancer Research, vol. 74, no. 21, pp. 6260-6270, 2014.
128. S. Yano, Y. Zhang, M. Zhao, et al., "Tumor-targeting Salmonella Typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy, " Cell Cycle, vol. 13, no. 24, pp. 3958-3963, 2014.
129. K. Yazawa, M. Fujimori, T. Nakamura, et al., "Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors, " Breast Cancer Research and Treatment, vol. 66, no. 2, pp. 165-170, 2001.
130. P. H. Lizotte, J. R. Baird, C. A. Stevens, et al., "Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis, " OncoImmunology, vol. 3, no. 5, Article ID e28926, 2014.
131. B. P. Keenan, Y. Saenger, M. I. Kafrouni, et al., "A Listeria vaccine and depletion of t-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice, " Gastroenterology, vol. 146, no. 7, pp. 1784. e6-1794. e6, 2014.
132. Y. Zhang, Y. Tome, A. Suetsugu, et al., "Determination of the optimal route of administration of Salmonella Typhimurium A1-R to target breast cancer in nude mice, " Anticancer Research, vol. 32, no. 7, pp. 2501-2508, 2012.
133. M. Momiyama, M. Zhao, H. Kimura, et al., "Inhibition and eradication of human glioma with tumor-targeting Salmonella Typhimurium in an orthotopic nude-mouse model, " Cell Cycle, vol. 11, no. 3, pp. 628-632, 2012.
134. Y. Hiroshima, Y. Zhang, T. Murakami, et al., "Efficacy of tumor-targeting Salmonella TyphimuriumA1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patientderived orthotopic xenograft (PDOX) and cell line mouse models, " Oncotarget, vol. 5, no. 23, pp. 12346-12357, 2014.
135. C.-C. Chen, W.-C. Lin, M.-S. Kong, et al., "Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extraintestinal tissue, " British Journal of Nutrition, vol. 107, no. 11, pp. 1623-1634, 2012.
136. D. T. Le, A. Wang-Gillam, V. Picozzi, et al., "Safety and survival with GVAX pancreas prime and Listeria monocytogenes expressingMesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, " Journal of Clinical Oncology, vol. 33, no. 12, pp. 1325-1333, 2015.